摘要
目的探讨急性髓性白血病(AML)患者外周血T淋巴细胞亚群及Th1/Th2细胞因子的变化及临床意义。方法采用流式细胞仪及酶联免疫吸附法(ELISA)分别检测50例健康者及30例AML患者治疗前后T淋巴细胞亚群及Th1/Th2细胞因子水平。结果初诊AML患者外周血CD3+、CD4+、CD4+/CD8+均显著低于健康组,CD8+显著高于健康组,差异具有统计学意义(P<0.05)。治疗后,AML组患者外周血CD3+、CD4+、CD4+/CD8+均显著升高,CD8+显著降低,与初诊时比较差异具有统计学意义(P<0.05),但与健康组比较差异仍具有统计学意义(P<0.05)。初诊AML患者外周血白介素2(IL-2)、干扰素(IFN-γ)均显著低于健康组,IL-4、IL-10显著高于健康组,差异具有统计学意义(P<0.05)。治疗后,AML组患者外周血IL-2、IFN-γ均显著升高,IL-4、IL-10显著降低,与初诊时比较差异具有统计学意义(P<0.05),但与健康组比较差异仍具有统计学意义(P<0.05)。结论 T淋巴细胞亚群及Th1/Th2细胞因子对AML患者病情评估、疗效判定及预后评估具有一定临床价值。以调节T淋巴细胞亚群及Th1/Th2细胞因子为免疫治疗方案,可能为AML的临床治疗提供新思路。
Objective To evaluate the change and clinical significance of T- lymphocyte subsets and Th1 /Th2 cytokines in peripheral blood of patients with acute myeloid leukemia（ AML）. Methods The flow cytometry instrument and enzyme- linked immunosorbent assay（ Elisa） was used respectively to detect the T- lymphocyte subsets and Th1 /Th2 cytokines of 50 cases of healthy subjects and 30 cases of AML patients before and after treatment. Results Before treatment,the peripheral blood CD3＋,CD4＋and CD4＋/ CD8＋in AML patients were significantly lower than healthy group,CD8＋was significantly higher than healthy group,the difference statistically significant（ P 0. 05）. After treatment,peripheral blood in patients with AML group CD3＋,CD4＋and CD4＋/ CD8＋were significantly increased,CD8＋decreased significantly,compared with before treatment was statistically significant（ P 0. 05）,but the difference was statistically significant compared with healthy group（ P 0. 05）. Before treatment,the peripheral blood IL- 2 and IFN- γ in AML patients were significantly lower than healthy group. IL-4 and IL- 10 were significantly higher than healthy group,the difference statistically significant（ P 0. 05）. After treatment,IL- 2 and IFN-γ of peripheral blood in patients with AML group were significantly increased,IL- 4 and IL- 10 decreased significantly compared with before treatment. The difference was statistically significant compared with healthy group（ P 0. 05）. Conclusion T- lymphocyte subsets and Th1 /Th2 cytokines may be effective index to evaluate the prognosis of patients with AML. To regulate T lymphocyte subsets and Th1 / Th2 cytokine immunotherapy program,this method may provide new ideas for the clinical treatment of AML.
出处
《临床和实验医学杂志》
2015年第16期1356-1358,共3页
Journal of Clinical and Experimental Medicine
